FGFR4 and hepatocellular carcinoma: Here, we questioned whether blockade of the sEV–vWF/FGF2/FGFR4 pathway alone or in combination with sorafenib, an Food and Drug Administration (FDA)‐approved drug for HCC patients, could be a better treatment for HCC patients.